Dr. Morris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4101 Tiger Lily Rd
Ste 100
Lincoln, NE 68516Phone+1 402-420-7000Fax+1 402-420-6969
Education & Training
- University of Iowa Hospitals and ClinicsFellowship, Gynecologic Oncology, 1990 - 1992
- University of Oklahoma Health Sciences CenterResidency, Obstetrics and Gynecology, 1985 - 1988
- University of New Mexico School of MedicineInternship, Transitional Year, 1983 - 1984
- University of Texas Southwestern Medical SchoolClass of 1983
Certifications & Licensure
- NE State Medical License 1992 - 2026
- IA State Medical License 1990 - 2007
- TX State Medical License 1983 - 2005
- NC State Medical License 1985 - 1992
- OK State Medical License 1986 - 1991
- NM State Medical License 1984 - 1988
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Join now to see all
Publications & Presentations
PubMed
- 72 citationsGemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.Rodney P. Rocconi, Elizabeth A. Grosen, Sharad A. Ghamande, John K. Chan, Minal A. Barve
The Lancet. Oncology. 2020-12-01 - 10 citationsIntraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trialDavid B. Engle, Joseph P. Connor, Peter C. Morris, David Bender, Koen De Geest
Archives of Gynecology and Obstetrics. 2012-05-09 - 42 citationsNonbacterial Thrombotic Endocarditis with Recurrent Embolic Events as Manifestation of Ovarian NeoplasmArash Aryana, Dennis J. Esterbrooks, Peter C. Morris
Journal of General Internal Medicine. 2006-12-01
Press Mentions
- Bryan Health & Cancer Partners of Nebraska Bring New Cancer Specialty to LincolnJanuary 14th, 2022
- Researchers Find Gene to Make Barley ‘Drought-Proof’September 2nd, 2019
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: